4.6 Article

Propranolol Promotes Bone Formation and Limits Resorption Through Novel Mechanisms During Anabolic Parathyroid Hormone Treatment in Female C57BL/6J Mice

Journal

JOURNAL OF BONE AND MINERAL RESEARCH
Volume 37, Issue 5, Pages 954-971

Publisher

WILEY
DOI: 10.1002/jbmr.4523

Keywords

ANABOLICS; BONE MODELING AND REMODELING; BONE-BRAIN-NERVOUS SYSTEM INTERACTIONS; CELL/TISSUE SIGNALING - ENDOCRINE PATHWAYS; DISEASES AND DISORDERS OF/RELATED TO BONE; MOLECULAR PATHWAYS - REMODELING; OSTEOPOROSIS; PTH/VIT D/FGF23; SYSTEMS BIOLOGY - BONE INTERACTORS; THERAPEUTICS

Funding

  1. National Institute of Arthritis And Musculoskeletal And Skin Diseases (NIAMS)
  2. National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH) [R01AR076349, K01AR067858, P20GM121301, T32GM132006]
  3. NIH/NIGMS [P20GM121301, P30GM106391, P30GM103392]
  4. Northern New England Clinical and Translational Research Network NIH/NIGMS [U54GM115516]

Ask authors/readers for more resources

This study investigates the mechanism of propranolol in improving bone density with parathyroid hormone (PTH) treatment. It found that propranolol enhances the effects of PTH in bone remodeling, suppresses bone resorption, and may directly impact osteoclasts.
Although the nonselective beta-blocker, propranolol, improves bone density with parathyroid hormone (PTH) treatment in mice, the mechanism of this effect is unclear. To address this, we used a combination of in vitro and in vivo approaches to address how propranolol influences bone remodeling in the context of PTH treatment. In female C57BL/6J mice, intermittent PTH and propranolol administration had complementary effects in the trabecular bone of the distal femur and fifth lumbar vertebra (L-5), with combination treatment achieving microarchitectural parameters beyond that of PTH alone. Combined treatment improved the serum bone formation marker, procollagen type 1 N propeptide (P1NP), but did not impact other histomorphometric parameters relating to osteoblast function at the L-5. In vitro, propranolol amplified the acute, PTH-induced, intracellular calcium signal in osteoblast-like cells. The most striking finding, however, was suppression of PTH-induced bone resorption. Despite this, PTH-induced receptor activator of nuclear factor kappa-B ligand (RANKL) mRNA and protein levels were unaltered by propranolol, which led us to hypothesize that propranolol could act directly on osteoclasts. Using in situ methods, we found Adrb2 expression in osteoclasts in vivo, suggesting beta-blockers may directly impact osteoclasts. Consistent with this, we found propranolol directly suppresses osteoclast differentiation in vitro. Taken together, this work suggests a strong anti-osteoclastic effect of nonselective beta-blockers in vivo, indicating that combining propranolol with PTH could be beneficial to patients with extremely low bone density. (C) 2022 American Society for Bone and Mineral Research (ASBMR).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available